Search

everythinglearnresearchcommunity

for

Search:↓

N-Acetyl-Cysteine (NAC) is being explored for treating hair loss, but users report mixed results. Some also mention using Quercetin and Resveratrol without significant hair improvement.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments, focusing on alternatives to Minoxidil, such as Bimatoprost and Latanoprost, and the use of Finasteride, Dutasteride, RU58841, and microneedling. The user plans to add Latanoprost to their regimen, which already includes oral and topical Minoxidil and Finasteride, Ketoconazole shampoo, and microneedling.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

The conversation is about treating hair loss without finasteride or dutasteride due to sensitivity causing gynecomastia. The user plans to use pyrilutamide, RU58841, and oral Minoxidil instead.

The user is frustrated with minimal hair regrowth after using dutasteride, oral minoxidil, and previously finasteride and topical minoxidil. Despite feeling discouraged, others suggest continuing treatment as progress can be slow and subtle, with some users noting visible improvement.

The user switched to dutasteride and oral minoxidil in January 2025 after previous treatments with minoxidil and finasteride became less effective. They report significant hair regrowth progress in three months with no side effects.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.

The potential health risks associated with long-term use of finasteride and dutasteride, with some responses pointing out the low quality of the journal that published the review article as well as highlighting other alternatives such as keto or minoxidil, and RU58841.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

The individual is using oral minoxidil and finasteride to treat androgenetic alopecia with good results but is considering stopping due to concerns about long-term effects on the heart and potential hair dependency on the medication. They are also contemplating the impact of hair loss on gender dysphoria and considering the use of wigs as an alternative.

Hair loss discussion involves spironolactone and bicalutamide for women's androgenic alopecia. Focus on effectiveness and side effects.

The conversation discusses hair regrowth treatments, specifically using a combination of oral and topical minoxidil, oral and topical dutasteride, and PRP. There is skepticism about the authenticity of the results, with some users questioning the changes in hair and skin appearance.

The user has been using 1mg oral finasteride daily for four years, experiencing significant hair regrowth and increased testosterone levels without negative side effects. They advise patience and monitoring for side effects, noting that their hair continues to improve with this treatment.

The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.

The conversation discusses hair regrowth results using dutasteride, minoxidil, and dermarolling over six months. OP reports significant improvement, especially in the temples, by derma-rolling frequently and applying minoxidil afterward.

Finasteride may cause insomnia, and ashwagandha is suggested to help with sleep issues without significantly affecting testosterone or DHT levels. Users discuss personal experiences with sleep disturbances and suggest consulting a doctor if side effects persist.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.

The conversation discusses whether age affects the side effects and effectiveness of hair loss treatments like finasteride and dutasteride. Some believe early treatment yields better results, while others mention varied outcomes across ages and personal regrowth experiences without a clear consensus on age impact.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.

Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

The user is treating diffuse thinning with finasteride, dutasteride, and oral minoxidil but hasn't seen significant improvement. Others suggest that results vary, with some maintaining hair and others considering transplants or future treatments.

An 18-year-old has been using 5% topical minoxidil for 2 months for hair loss, with a history of vitamin D deficiency and thyroid imbalance. Users suggest starting finasteride and blocking DHT for androgenetic alopecia (AGA).

The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.

User tried dutasteride, topical finasteride, oral minox, dermawounding, saw palmetto, pumpkin seed oil, and ketacozonole for hair loss. Improvement was temporary, now trying RU58841 and seeking help.